Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Liposomal paclitaxel"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundDespite its excellent therapeutic efficacy, albumin-bound paclitaxel often leads to peripheral neurotoxicity, significantly affecting patients’ quality of life. This study reported a case of non-small cell lung cancer (NSCLC) with periphe
Externí odkaz:
https://doaj.org/article/8193b1d7eec648a88829a38929d9ab92
Autor:
Jiale Zou, Shuang Wang, Ningli Chai, Hua Yue, Peng Ye, Peilin Guo, Feng Li, Bo Wei, Guanghui Ma, Wei Wei, Enqiang Linghu
Publikováno v:
Journal of Nanobiotechnology, Vol 20, Iss 1, Pp 1-16 (2022)
Abstract Background Gastric cancer (GC) is a highly heterogeneous disease with many different histological and molecular subtypes. Due to their reduced systemic adverse effects, nanoformulation agents have attracted increasing attention for use in th
Externí odkaz:
https://doaj.org/article/41c37243fa3f4b6684db722255466994
Publikováno v:
Thoracic Cancer, Vol 13, Iss 6, Pp 824-831 (2022)
Abstract Background This study analyzed the efficacy and safety of neoadjuvant chemotherapy with liposomal paclitaxel plus platinum in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC). Methods The data of patients w
Externí odkaz:
https://doaj.org/article/3c2e718618ac4a6cad53e20d2c55a175
Autor:
Jie Zhang, Yueyin Pan, Qin Shi, Guojun Zhang, Liyan Jiang, Xiaorong Dong, Kangsheng Gu, Huijuan Wang, Xiaochun Zhang, Nong Yang, Yuping Li, Jianping Xiong, Tienan Yi, Min Peng, Yong Song, Yun Fan, Jiuwei Cui, Gongyan Chen, Wei Tan, Aimin Zang, Qisen Guo, Guangqiang Zhao, Ziping Wang, Jianxing He, Wenxiu Yao, Xiaohong Wu, Kai Chen, Xiaohua Hu, Chunhong Hu, Lu Yue, Da Jiang, Guangfa Wang, Junfeng Liu, Guohua Yu, Junling Li, Jianling Bai, Wenmin Xie, Weihong Zhao, Lihong Wu, Caicun Zhou
Publikováno v:
Cancer Communications, Vol 42, Iss 1, Pp 3-16 (2022)
Abstract Background Lipusu is the first commercialized liposomal formulation of paclitaxel and has demonstrated promising efficacy against locally advanced lung squamous cell carcinoma (LSCC) in a small‐scale study. Here, we conducted a multicenter
Externí odkaz:
https://doaj.org/article/6390005c415f4ea5b107038b3eac3a40
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sai-Lan Liu, Xue-Song Sun, Xiao-Yun Li, Qiu-Yan Chen, Huan-Xin Lin, Yue-Feng Wen, Shan-Shan Guo, Li-Ting Liu, Hao-Jun Xie, Qing-Nan Tang, Yu-Jing Liang, Jin-Jie Yan, Chao Lin, Zhen-Chong Yang, Lin-Quan Tang, Ling Guo, Hai-Qiang Mai
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
Abstract Background We wished to evaluate the efficacy and safety of liposomal paclitaxel and docetaxel for induction chemotherapy (IC) for nasopharyngeal carcinoma (NPC). Methods A total of 1498 patients with newly-diagnosed NPC between 2009 and 201
Externí odkaz:
https://doaj.org/article/9ad73d0dd1b5436399af1bc4b10c37fa
Publikováno v:
Zhongliu Fangzhi Yanjiu, Vol 45, Iss 8, Pp 583-586 (2018)
Objective To investigate the clinical efficacy and safety of liposome paclitaxel in maintenance therapy of advanced squamous cell lung carcinoma patients. Methods After 4-6 cycles of first-line treatment, 57 patients with advanced squamous cell lung
Externí odkaz:
https://doaj.org/article/1013ccea1a874aceb26f67c0a9addeb8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ziping Wang, Tienan Yi, Yun Fan, Guangqiang Zhao, Guangfa Wang, Gongyan Chen, Yong Song, Aimin Zang, Wenxiu Yao, Kangsheng Gu, Junfeng Liu, Caicun Zhou, Guohua Yu, Jianxing He, Jianling Bai, Huijuan Wang, Da Jiang, Xiaochun Zhang, Xiaohua Hu, Jie Zhang, Liyan Jiang, Kai Chen, Jiuwei Cui, Wenmin Xie, Qisen Guo, Lihong Wu, Chunhong Hu, Xiaorong Dong, Yueyin Pan, Junling Li, Guojun Zhang, Nong Yang, Min Peng, Xiaohong Wu, Lu Yue, Jianping Xiong, Qin Shi, Weihong Zhao, Yuping Li, Wei Tan
Publikováno v:
Cancer Communications, Vol 42, Iss 1, Pp 3-16 (2022)
Cancer Communications
Cancer Communications
Background Lipusu is the first commercialized liposomal formulation of paclitaxel and has demonstrated promising efficacy against locally advanced lung squamous cell carcinoma (LSCC) in a small‐scale study. Here, we conducted a multicenter, randomi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::783e1dfd4e917a38cee656a166af64a2
https://doaj.org/article/6390005c415f4ea5b107038b3eac3a40
https://doaj.org/article/6390005c415f4ea5b107038b3eac3a40
Autor:
Jing Huang, Ling Qi, Bo Zhang, Jianping Xu, Lidan Bai, Xi Wang, Yun Liu, Lan Mu, Xingyuan Wang
Publikováno v:
Cancer Communications
Background Effective therapeutic options are limited for patients with advanced esophageal squamous cell carcinoma (ESCC). The incorporation of an immune checkpoint inhibitor and a molecular anti-angiogenic agent into the commonly adopted chemotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fecd29e980c9b2f38a0e88c9dd36088
http://europepmc.org/articles/PMC7743020
http://europepmc.org/articles/PMC7743020